Adaptimmune Therapeutics Plc Stock Alpha and Beta Analysis
| ADAP Stock | USD 0.66 0.02 3.13% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Adaptimmune Therapeutics Plc. It also helps investors analyze the systematic and unsystematic risks associated with investing in Adaptimmune Therapeutics over a specified time horizon. Remember, high Adaptimmune Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Adaptimmune Therapeutics' market risk premium analysis include:
Beta 1.45 | Alpha (0.93) | Risk 4.51 | Sharpe Ratio (0.19) | Expected Return (0.87) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Adaptimmune |
Adaptimmune Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Adaptimmune Therapeutics market risk premium is the additional return an investor will receive from holding Adaptimmune Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Adaptimmune Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Adaptimmune Therapeutics' performance over market.| α | -0.93 | β | 1.45 |
Adaptimmune Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Adaptimmune Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Adaptimmune Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Adaptimmune Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Adaptimmune Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Adaptimmune Therapeutics shares will generate the highest return on investment. By understating and applying Adaptimmune Therapeutics stock market price indicators, traders can identify Adaptimmune Therapeutics position entry and exit signals to maximize returns.
Adaptimmune Therapeutics Return and Market Media
The median price of Adaptimmune Therapeutics for the period between Tue, Aug 27, 2024 and Mon, Nov 25, 2024 is 0.89 with a coefficient of variation of 20.08. The daily time series for the period is distributed with a sample standard deviation of 0.18, arithmetic mean of 0.92, and mean deviation of 0.15. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Joanna Brewer of 565416 shares of Adaptimmune Therapeutics at 0.0013 subject to Rule 16b-3 | 08/30/2024 |
2 | Acquisition by John Lunger of 2544432 shares of Adaptimmune Therapeutics at 0.14 subject to Rule 16b-3 | 09/13/2024 |
3 | Adaptimmune Therapeutics plcs top owners are individual investors with percent stake, while 28 percent is held by institutions | 09/25/2024 |
4 | ReCode Announces Two Key Additions to Scientific Advisory Board | 10/01/2024 |
5 | Acquisition by Hegde Priti of 152376 shares of Adaptimmune Therapeutics at 0.11 subject to Rule 16b-3 | 10/11/2024 |
6 | Adaptimmune Therapeutics plc Short Interest Update | 10/16/2024 |
7 | Acquisition by Tayton-martin Helen Katrina of 2544432 shares of Adaptimmune Therapeutics at 0.14 subject to Rule 16b-3 | 10/18/2024 |
8 | Acquisition by Allen Andrew R of 56868 shares of Adaptimmune Therapeutics at 1.78 subject to Rule 16b-3 | 10/21/2024 |
9 | Painful week for retail investors invested in Adaptimmune Therapeutics plc after 11 percent drop, institutions also suffered losses | 10/25/2024 |
10 | Adaptimmune to Participate in Scientific and Medical Conferences this November and December | 11/05/2024 |
11 | Insider Trading | 11/06/2024 |
12 | Adaptimmune Reports Q3 2024 Financial and Business Updates | 11/13/2024 |
13 | Adaptimmune Therapeutics earnings matched, revenue topped estimates | 11/14/2024 |
14 | Europes TCR immunotherapy licensing deals surge 123 percent above US in 2024 | 11/22/2024 |
About Adaptimmune Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Adaptimmune or other stocks. Alpha measures the amount that position in Adaptimmune Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 13.69 | 26.87 | 1.21 | 1.15 | Days Of Inventory On Hand | 2.45 | 3.65 | 4.2 | 5.47 |
Adaptimmune Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Adaptimmune Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Adaptimmune Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Adaptimmune Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Adaptimmune Therapeutics. Please utilize our Beneish M Score to check the likelihood of Adaptimmune Therapeutics' management manipulating its earnings.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Adaptimmune Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.